Skip to content Skip to footer
VIEWPOINTS_Angela Cacace_2024

Transformative Neurodegenerative Disorder Care: Angela Cacace in Conversation with PharmaShots

Shots:Angela Cacace Sr. VP, of Neuroscience and Platform Biology at Arvinas, shares insights from the preclinical trials evaluating ARV-102 for treatment of neurodegenerative diseases and dosing people with the first oral formulation (ARV-102) to treat neurodegenerative diseasesARV-102, a novel oral PROTAC® protein degrader, is designed to cross the blood-brain barrier and target leucine-rich repeat kinase…

Read more

VIEWPOINTS_Craig Thompson_2023

Craig Thompson, CEO of Cerevance Shares Insights from the Preclinical Data Presented at the Society for Neuroscience (SFN) 2022

Shots:  Craig shared with our readers the preclinical study results of C101248 demonstrating its pharmacological activity and validation of the NETSseq platform as an effective method to interpret new therapeutic targets for Alzheimer’s disease He also elaborated on how the combination of the NETSseq platform and C101248 will help in the identification and development of…

Read more

PharmaShots Interview: Clario’s Joyce Suhy Shares Insights on PET Imaging Clinical Trials

In an interview with PharmaShots, Joyce Suhy, Senior Vice President, Medical Imaging at Clario shares her views on the PET imaging clinical trials & expands its 2018 collaboration with XingImaging for Alzheimer’s disease and other neurodegenerative diseasesShots:Clario & XingImaging have expanded the collaboration to provide PET imaging clinical trials for neurodegenerative therapeutics in China. The initial study used Amyvid (florbetapir) PET imaging to…

Read more